Last mentioned: Mar 23, 2026
Wellgistics Health Inc. has signed a $105 million Letter of Intent to acquire Neuritek Therapeutics, a biotech firm specializing in neurological and psychiatric disorder treatments. The deal marks a significant strategic pivot for Wellgistics into the high-stakes central nervous system (CNS) therapeutic market.
Wellgistics Health Inc. has entered into a non-binding Letter of Intent to acquire Neuritek Therapeutics for $105 million. The deal marks a significant strategic pivot for Wellgistics into the high-growth neurological and psychiatric drug development sector.
Wellgistics Health Inc. has signed a $105 million Letter of Intent to evaluate the acquisition of Neuritek Therapeutics, a biotech firm specializing in neurological and psychiatric treatments. The deal marks a significant strategic expansion for Wellgistics into the high-growth central nervous system (CNS) therapeutic sector.